FORMULATION DEVELOPMENT AND EVALUATION OF BRAIN TARGETED ESLICARBAMAZEPINE ACETATE NANOSUSPENSION FOR EPILEPSY

Pharmaceutics

Epilepsy is a major neurological disorder affecting people of all age groups; around 50 million people worldwide are suffering from it. A combination of nanosuspension along with a nose-to-brain approach can help in promoting the treatment efficacy by site specific delivery. Eslicarbamazepine acetate (ESL) is a novel drug with dual mechanism of action i.e voltage-gated sodium channel and t-type calcium channel blocker with anticonvulsant activity. It is a prodrug, which is the drug entity responsible for the pharmacological effect with high potency and efficient safety as well as efficacy. Nanosuspensions have emerged as an attractive and promising approach to improve stability and bioavailability of poorly soluble drugs of size below 1μm, which is prepared by media milling method. The current research efforts are being directed for extending their applications in site-specific (Nasal) drug delivery system. Nanosuspensions generally have the ability to deliver the drug to the brain through olfactory and trigeminal nerves pathways circumventing the blood brain barrier. Nasal drug delivery has received a great deal of attention as a convenient, reliable and promising method for the systemic administration of drugs. The prepared formulations were then evaluated for particle size distribution (PDI), Zeta Potential, drug content, % Entrapment Efficiency and Invitro drug release

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.